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Introduction: Human-cl rhFVIII (Nuwiq), a new generation recombinant factor VIII (rFVIII), is the first
rFVIII produced in a human cell-line approved by the European Medicines Agency.
Aims: To describe the development, upscaling and process validation for industrial-scale human-cl
rhFVIII purification.
Methods and results: The purification process involves one centrifugation, two filtration, five chromatog-
raphy columns and two dedicated pathogen clearance steps (solvent/detergent treatment and 20 nm
nanofiltration). The key purification step uses an affinity resin (VIIISelect) with high specificity for
FVIII, removing essentially all host-cell proteins with >80% product recovery. The production-scale
multi-step purification process efficiently removes process- and product-related impurities and results
in a high-purity rhFVIII product, with an overall yield of 50%. Specific activity of the final product
was >9000 IU/mg, and the ratio between active FVIII and total FVIII protein present was >0.9. The entire
production process is free of animal-derived products. Leaching of potential harmful compounds from
chromatography resins and all pathogens tested were below the limit of quantification in the final
product.
Conclusions: Human-cl rhFVIII can be produced at 500 L bioreactor scale, maintaining high purity and
recoveries. The innovative purification process ensures a high-purity and high-quality human-cl
rhFVIII product with a high pathogen safety margin.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Haemophilia A is an X-linked hereditary blood coagulation dis-
order caused by a deficiency in coagulation factor VIII (FVIII) [1,2].
Patients with haemophilia A are predisposed to recurrent bleeds,
particularly into joints and soft tissues culminating in debilitating
arthropathy and long-term morbidity [1,3]. Haemophilia A can be
effectively treated with recombinant (rFVIII) or plasma-derived
FVIII (pdFVIII) [1,2]. The development of inhibitors to FVIII is the
most serious complication in the treatment of haemophilia A
[4–8]. Inhibitors are estimated to develop in up to 38% of previouslyuntreated patients [9] and 1% of previously treated patients (PTPs)
[10].
Endogenous FVIII undergoes extensive post-translational modi-
fications (PTMs), particularly sulphation and glycosylation, which
are necessary for full functional activity of FVIII [11–14]. The
degree of sulphation at specific residues, notably Tyr1680, has also
been shown to determine the binding affinity of FVIII for its in vivo
molecular chaperone, von Willebrand factor (VWF) [13,15]. The
Tyr1680 sulphation site is in close proximity to a peptide,
V1670-D1687, within the acidic a3-domain of FVIII (see Fig. 1)
which recent work by Chiu et al., using hydrogen–deuterium
exchange mass spectrometry, has shown to be involved in FVIII-
VWF binding [16]. The close proximity of the sulphation site at
Fig. 1. Schematic representation of the domain structure of human pdFVIII (without the B domain as per Nuwiq), showing sites of post-translational modification (PTM).
Functional FVIII protein comprises of 5 major domains: A1, A2, A3, C1 and C2. The heavy and light chains are co-ordinated by a divalent metal ion. Within the acidic a3
domain, Chiu et al. [16] identified a putative FVIII-VWF binding region, V1670-D1687. Figure adapted with kind permission from Kannicht et al. [15].
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the affinity of FVIII-VWF binding.
Human-cl rhFVIII (Nuwiq, Octapharma AG, Switzerland) is a
new generation human rFVIII, without chemical modification or
fusion with any other protein/fragment, which is produced in a
human cell-line (HEK293F). As a result, human-cl rhFVIII has
human PTMs, is fully sulphated, and contains only human glycans
[15,17,18]. The comparable sulphation profile of human-cl rhFVIII
to human pdFVIII is thought to confer a higher binding affinity
for VWF than other rFVIII products. Consequently this may
enhance the stability of human-cl rhFVIII and reduce the immuno-
genic potential created from unbound, circulating FVIII [15,18].
Furthermore, human-cl rhFVIII is devoid of antigenic non-human
epitopes present in rFVIII products derived from hamster cell-
lines [15]. The combination of full sulphation and the absence of
antigenic carbohydrate epitopes has the potential to minimise
the intrinsic immunogenicity of infused rFVIII [15].
Clinical trials involving 135 PTPs with haemophilia A have con-
firmed the efficacy of human-cl rhFVIII in the prevention and treat-
ment of bleeds with no inhibitor development or treatment-
related serious adverse events reported [19]. Human-cl rhFVIII is
the first rFVIII produced in a human cell-line approved by the Euro-
pean Medicines Agency for the prevention and treatment of bleed-
ing in patients with haemophilia A.
The human cell-line for producing human-cl rhFVIII, the PTMs
and functional characteristics of the purified product have been
reported previously [15,17,18]. The aim of this article is to report
the development, upscaling and process validation for industrial-
scale purification of human-cl rhFVIII. Several publications have
reported on the purification of rFVIII [20–25]. However, these pub-
lications are mainly based on non-human cells, have no or limited
information in regard to the development process, upscaling to
production scale, process variability (validation) and process
yields. Recently there has also been increased focus on leachables
from process aids, equipment and chromatography resins used
during the process, especially for the manufacturing of biopharma-
ceutical drugs that are intended for lifelong use such as FVIII. Toour knowledge, for the first time, theoretical and practical aspects
of removing less-defined impurities such as leachables is presented
related to the safety of a rFVIII product.2. Materials and methods
2.1. Overall purification process
A purification process was developed to optimise the purity and
pathogen safety of human-cl rhFVIII (Fig. 2), including one cell
removal step (centrifugation/filtration), two filtration and five
chromatography column steps. The chromatography resins and fil-
ters used were Capto MMCTM (step 2), SP Sepharose FF (step 3),
VIIISelect (step 6), Q Sepharose FF (step 8), Superdex 200 p.g.TM
(step 9, all GE Healthcare Life Sciences, Sweden), Bio20 STAX (step
1, PALL), Sartobind Q (step 4, Sartorius Stedim, Denmark) and Pla-
nova 20 NTM (step 7, N.V. Asahi Kasei Bioprocess, Belgium) [26–29].
Molar (M) is equally used to mol/kg throughout this work, due to
production related data input.2.2. Cell cultivation
A proprietary derivative of the human embryonic kidney cell
line HEK293, named 293F – adapted to grow in serum-free culture
media, was used to express the protein [17,30–32]. Revival of a fro-
zen cell bank vial with HEK293F cells was performed for each new
production campaign for production of Nuwiq. Cells were further
propagated and expanded with in-house proprietary medium in
shaker flasks followed by further propagation in a 20 L bioreactor.
When sufficient active cell material of the required quality had
been achieved, a series of sequential batches consisting of the
major part of the cell suspension were transferred to a production
bioreactor. The production bioreactor (100 L) was operated as a
perfuse batch process using a membrane-based cell retention sys-
tem. The perfusion rate was adjusted daily after each cell density
measurement to maintain a cell specific perfusion rate until the
Fig. 2. Overview of the human-cl rhFVIII purification process.
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purification Fig. 2, step 1). All bioreactors used were baffled, con-
tinuously controlled and maintained in regard of pressure, temper-
ature, pH, oxygen and carbon dioxide according to cultivation
standard procedures. The cells were agitated (3–30W/m3) during
the process [32].2.3. Harvesting (Fig. 2, step 1)
A batch harvest process was used, whereby sodium chloride
(NaCl) was added to the cell suspension to a final concentration
of 0.3 M for detachment of FVIII from cells. [26]. Cells were
removed by centrifugation and filtration before the harvested
168 S. Winge et al. / Protein Expression and Purification 115 (2015) 165–175material was applied directly to the capture step without any dilu-
tion or other adjustments.
2.4. Capture purification (Fig. 2, step 2)
Primary product purification and concentration (capture) was
performed on a 2 L multimodal cation exchange chromatography
column (bed height 15 cm and diameter 14 cm) in which
150–200 kg cell free harvest was applied after equilibration with
a 0.3 M NaCl solution at pH 7 with a flowrate of 70 L/h. The column
was further washed by a stepwise procedure with a total amount
of 50 column volumes, lowering the pH to 6.5 by using different
NaCl concentrations (0.3 M, 1 M, 0.1 M and 0.3 M). The last wash
also included a combination of arginine (0.4 M) and ethylene glycol
(10%). FVIII was eluted and collected from the column by increas-
ing the arginine concentration to 0.8 M. Subsequently the column
was regenerated with a high salt solution combined with a non-
ionic detergent (0.5 M NaCl + 1% Triton X-100), low (1 M HAc)
and high (1 M NaOH) pH and finally stored in a weak (0.05 M)
sodium hydroxide solution before start of next production batch.
2.5. Cation exchange purification (Fig. 2, step 3)
The cation exchange purification was performed on a 2 L col-
umn (bed height 12 cm and column diameter 14 cm) column in
which the eluate from purification step 2 had been diluted ten
times to a conductivity equal to approximately 0.1 M NaCl,
pH 6.5, before applying to the column, which previously had been
equilibrated with a 0.1 M NaCl, pH 6.5 buffer at a flow of 55 L/h.
The column was further washed by a stepwise procedure with a
total amount of 50 column volumes by increasing the NaCl concen-
tration to 0.15 M. FVIII was eluted and collected from the column
by further increasing NaCl concentration to 0.3 M. Subsequently
the column was regenerated with a high salt solution combined
with a non-ionic detergent (0.5 M NaCl + 1% Triton X-100), low
(0.1 M HAc) and high (1 M NaOH) pH and finally stored in a weak
(0.05 M) sodium hydroxide solution before start of next production
batch.
2.6. DNA removal (Fig. 2, step 4)
3–4 L of the FVIII containing fraction from purification step 3
was processed over a 2500 cm2 anion exchange membrane equili-
brated with the same solution used for eluting FVIII in step 3 at a
maximum pressure of 3 bar. FVIII was recovered in the flow
through fraction.
2.7. Pathogen inactivation (Fig. 2, step 5)
2–5 batches (10–25 kg) from step 4 were pooled before adding
1% Triton X-100 and 0.3% Tri(n-butyl)phosphate (TnBP) and stir-
ring at 22 C for 30–60 min.
2.8. Affinity purification (Fig. 2, step 6)
Affinity purification was performed on a 1.5 L column (bed
height 10 cm and diameter 14 cm) in which the pathogen activated
solution from purification step 6 was applied to the column previ-
ously equilibrated with a 0.3 M NaCl, pH 6.5 buffer at a flow of
22 L/h. The column was further washed at a flowrate of 55 L/h by
a stepwise procedure with a total amount of 25 column volumes
by increasing NaCl concentration from 0.3 M to 1 M. FVIII was
eluted and collected from the column by adding 50% ethylenegly-
col. Subsequently the column was regenerated with a high salt
solution (2 M NaCl) and a low pH solution (0.15 M phosphoricacid + 0.17 M HAc + 2.2% (v/v) benzyl alcohol) and finally stored
in a ethanol solution (20%) before start of next production batch.
2.9. Nanofiltration (Fig. 2, step 7)
3–5 L of the FVIII containing fraction from purification step 6
was diluted 10 times resulting in a NaCl concentration of 0.1 M
at pH 7.5. The solution was processed over a 1 m2 nanofilter equi-
librated with a 0.1 M NaCl, pH 7.5 buffer solution at a pressure of
0.6–0.8 bar. FVIII was recovered in the flow-through fraction.
2.10. Anion exchange purification (Fig. 2, step 8)
Anion exchange purification was performed on a 0.5 L column
(bed height 7 cm and column diameter 10 cm) in which the filtrate
from purification step 7 was applied to the column, previously
equilibrated with a 0.1 M NaCl, pH 7.5 buffer solution at a flow
of 13 L/h. The column was further washed by a stepwise procedure
with a total amount of 15 column volumes by increasing the NaCl
concentration from 0.1 M to 0.3 M. FVIII was eluted and collected
from the column by further increase of the NaCl concentration to
0.4 M. Subsequently the column was regenerated with a high salt
solution (2 M NaCl) and high pH (1 M NaOH) and finally stored
in a weak (0.01 M) sodium hydroxide solution before start of next
production batch.
2.11. Size exclusion purification (Fig. 2, step 9)
Size exclusion purification was performed on a 5 L column (bed
height 60–70 cm, column diameter 10 cm) in which 200–400 mL of
the FVIII solution from purification step 8 was applied to the col-
umn, previously equilibrated with the formulation solution ([42],
a native buffered sugar/amino acid/non-ionic detergent solution
at pH 7) at a flow rate of 65 mL/min. The monomeric FVIII fraction
was collected according to the retention time as measured by
absorbance at 280 nm. Subsequently the column was regenerated
with a high pH solution (1 M NaOH) and finally stored in a weak
(0.01 M) sodium hydroxide solution before start of next production
batch.
2.12. Assessment of pathogen safety
The following pathogens were selected for testing of both safe-
guarding steps (solvent/detergent [S/D] inactivation and 20 nm
nanofiltration) in scaled-down models mimicking the production
scale: human immunodeficiency virus type 1 (HIV-1), pseudora-
bies virus (PRV), and bovine viral diarrhoea virus (BVDV). In addi-
tion, hepatitis A virus (HAV), porcine parvovirus (PPV) and prion
protein (Strain 263 K hamster-adapted scrapie; PrPSc) were inves-
tigated to specifically test the nanofiltration step. All pathogen
safety studies were performed in duplicate. Cytotoxicity and inter-
ference tests were performed to determine necessary dilutions to
avoid matrix effects. A validated assay system for endpoint titra-
tion and large-volume plating was used. PrPSc was investigated
using Western Blot analysis. The obtained logarithmic reduction
factors were determined using the method of Spearman/Kaerber
and, where applicable, the Poisson distribution at 95% upper confi-
dence limits (p = 0.05).
2.13. Analytical methods
2.13.1. FVIII activity (FVIII:C)
FVIII biologic activity was measured with a chromogenic assay
(COATEST SP FVIII kit, 82 4086 63, Chromogenix/Instrumentation
Laboratory, US), based on a two-stage photometric method that
measures the biological activity of FVIII as a cofactor [33–35].
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2.13.2. FVIII antigen (FVIII:Ag)
The amount of FVIII antigen content was measured with an
ELISA kit (ASSERACHROM VIII:Ag, enzyme immunoassay for FVIII,
kit, Diagnostica Stago, France), as further described [36] with
replacement of the provided kit buffer with Tris–NaCl buffer +1%
bovine serum albumin for sample dilutions.
2.13.3. Quantification of DNA
DNA was quantified by a real time quantitative PCR (qPCR)
assay based on SYBR Green 1 chemistry [37] with some added
improvements. During each PCR cycle a 115 base pair fragment
from the ALU sequence families was amplified by the primers,
ALU115-F and ALU115-R. The ALU sequence family are short inter-
spersed repeated DNA elements distributed throughout primate
genomes, but the assay only amplify DNA from human origin.
The procedure allows for high throughput analysis of residual
HEK293F DNA in cell free tissue culture media and its downstream
purification processes.
2.13.4. Total protein (Bradford)
Protein concentration was determined by Bradford assay [38].
2.13.5. Host-cell protein
Determination of host cell proteins (HCP) deriving from HEK
293 cells was performed using an ELISA method [39].
2.13.6. Specific activity
FVIII purity (or also called specific activity) for a sample, was
calculated from the value achieved from the FVIII:C analysis (bio-
logical activity, IU/mL) and divided by the value achieved from
the analysis of total protein concentration (mg/mL).
2.13.7. Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS–PAGE) silver stained
Analysis was carried out under reducing conditions to deter-
mine the molecular weight distribution in the sample.
2.13.8. FVIII Western Blot
After SDS–PAGE, proteins were transferred by electrophoresis
to a nitrocellulose membrane and polyclonal sheep antibodies
directed to FVIII were added, followed by horseradish
peroxidase-conjugated rabbit anti-sheep secondary antibody. The
chemiluminescent substrate was added and FVIII polypeptide
bands were detected using a charge-coupled device camera
(ChemiDocTM XRS, BioRad).
2.13.9. Size exclusion chromatography (SEC)
FVIII monomers, aggregates and fragments in samples were
measured using a HPLC system (Waters 2695) with a size exclusion
chromatography (SEC) analytical column (Superdex 200, 10/300
GL, GE Healthcare) processed under native buffer conditions
(25 mM HEPES, 0.5 M NaCl, 0.3 M arginine, 50 mM CaCl2, 0.02%
Polysorbate 80, pH 7.5, temperature 25 C) at a flowrate of
0.25 mL/min and a sample injection volume of 200 lL. A fluores-
cence detector (280–340 nm) was used to detect separated peaks.
2.14. Binding kinetics
The kinetic parameters of the VIIISelect affinity ligand for bind-
ing to rhFVIII and to the rhFVIII light chain (rhFVIII-LC) were deter-
mined by surface plasmon resonance (SPR) on a BiacoreTM 3000
system (GE Healthcare). The VIIISelect ligand and a control ligand
selective for human chorionic gonadotropin (hCG) (BAC B.V.) wereimmobilised as biotin conjugates onto separate flow cells of a
streptavidin sensor chip (GE Healthcare). The amount of immo-
bilised VIIISelect and control ligand (reference flow cell) for affinity
measurements of rhFVIII (MW 170 kDa,) corresponded to 153 and
150 resonance units (RU), respectively. For binding analyses with
rhFVIII-LC (MW 80 kDa), these values were 303 and 749 RU,
respectively. Each analyte was allowed to bind for 3 min at a flow
rate of 30 ll/min followed by a dissociation step of 15 min at 30
ll/min. Flow cells were regenerated for 1 min at 30 ll/min using
0.1 M glycine pH 2 and subsequently equilibrated with binding
buffer prior to the next measurement. Binding curves were gener-
ated in duplicate for each sample at 5, 25, 50, 150 and 250 nM. For
rhFVIII-LC, a sample of 500 nM was also included. Binding analyses
were performed in 3 buffers: HBS-P (10 mM HEPES, 0.15 M NaCl,
0.005% surfactant P20 pH 7.4); HBS-EP (10 mM HEPES, 0.15 M
NaCl, 3 mM EDTA, 0.005% surfactant P20 pH 7.4); and HBS-CP
(10 mM HEPES, 0.15 M NaCl, 10 mM CaCl2, 0.005% surfactant P20
pH 7.4). The rate constants of association (kass) and dissociation
(kdiss) were calculated using the BIA evaluation software applying
a standard 1:1 Langmuir local fit. Equilibrium dissociation con-
stants (KD) were calculated as kass/kdiss.
2.15. Analysis of leachables from chromatography resins
Resin leakage for the five chromatography column purification
steps was evaluated in the equilibration buffer after passing
through the column prior to product loading, and in the product-
containing eluate fraction of the respective step. Leachable com-
pounds originating from the resin were measured to assess the sta-
bility of each resin. In addition, the resin leachate components
were analysed in the final product solution. All method validations
and analyses of leachable compounds were performed by BIA
Separations (Ljubljana, Slovenia). The acceptance criteria for each
leachable compound were set according to the limits of quantifica-
tion of the respective analytical method.
2.15.1. Capto MMC resin
Allyl glycidyl ether was analysed using a gas chromatography
column (DB-FFAP, 30 m  0.53 mm, 1 lm film) under constant
helium pressure carrier gas of 7.4 Psi with a temperature of
100 C injecting 2 lL sample at 220 C, detecting with a
FID-detector at 250 C and using a makeup nitrogen gas with
25 mL/min, an airflow of 450 mL/min and a hydrogen flow of
40 mL/min. Sample was prepared by mixing 1:1:2 with ethanol
and methylene chloride, before the sample was centrifuged
3500 rpm for 3 min in a 15 mL tube and the bottom (methylene
chloride phase) was further used for injection in the gas chro-
matograph. N-benzoyl-DL-homocysteine was analysed using a
HPLC column (YMC Hydrosphere C18, 150  4.6 mm; 3 lm) at
25 C with a flowrate of 1 mL/min and a mobile phase of 0.05%
TFA and methanol 45/55 (V/V), injecting 50 lL sample and
detecting at 250 nm SP.
2.15.2. Sepharose FF resin
Allyl glycidyl ether was analysed using gas chromatography,
according to the same procedure as described for the Capto MMC
resin above.
2.15.3. VIIISelect resin
6-Aminocaproic acid was analysed using a HPLC column
(Kromasil 100 C-18, 250  4.6 mm; 5 lm) at 30 C with a flowrate
of 1 mL/min and a mobile phase of 25% methanol, 0.55 g/L Hexane-
1-sulphonic acid sodium salt, 10 g/L monobasic potassium phos-
phate, pH 2.2. The sample was prepared by mixing 0.5 mL sample
with 1.0 mL mobile phase injecting 50 lL sample and detecting
at 210 nm. The VIIISelect ligand was analysed using a commer-
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Fischer/BAC 81-2860.01) based on quantitative sandwich enzyme
immunoassay technology.
2.15.4. Q Sepharose FF resin
Allyl glycidyl ether was analysed using gas chromatography,
according to the same procedure as described for the Capto MMC
resin above. Trimethylamine was analysed using a head space
gas chromatography column (WCOT fused silica, 60  0.32 mm,
coating CP-Volamine) under constant helium pressure carrier gas
of 27 Psi with a temperature of 45 C injecting 1 mL sample at
175 C, detecting with a FID-detector at 250 C and using a makeup
nitrogen gas with 25 mL/min, an airflow of 450 mL/min and a
hydrogen flow of 40 mL/min. Samples for injection was prepared
by mixing 1:1:1 with DMSO and 2.5 M NaOH at 60 C.
2.15.5. Superdex 200 p.g. resin
Agarose and dextran were quantified by a standard total organic
carbon analysis using high temperature combustion at 1350 C,
followed by IR detection of combustion gases – the amount of
CO2 in combustion gases is direct proportional to the amount of
carbon in sample. 1 ml of sample was pipetted into ceramic cru-
cible. 20 lL of concentrated HCl was added and the sample was
dried at 45 C for at least 24 h until complete dryness. Prepared
sample was analysed using ELTRA Elemental Analyser (model
Metalyt 100 CS, Germany).3. Results
3.1. Development of the human-cl rhFVIII purification process
A purification process was developed to optimise the purity and
pathogen safety of human-cl rhFVIII (Fig. 2), which includes one
cell removal step (centrifugation/filtration), two filtration and five
chromatography column steps. The harvesting procedure used a
batch harvest of the cell suspension as the expressed FVIII adheres
to the cells. The interaction between FVIII and the cells could be
broken by increasing the ion concentration (by addition of e.g.,
NaCl), allowing for enhanced extraction of FVIII, minimising the
cell destruction and release of intracellular impurities into the har-
vest. By optimising the amount of salt added, a high FVIII recov-
ery/concentration could be achieved (Supplementary material,
Figure S1) with relatively low amounts of cell-related impurities
and low protease activity. A further advantage of the salted batch
harvest process, compared with the perfusion process used in gen-
eral for rFVIII production [22], was the stability of FVIII due to inhi-
bition and rapid reduction of proteases. The relatively small
volume and the non-physiological environment facilitate rapid
capture column protease removal under reduced proteolytic activ-
ity conditions.
Based on the advantageous harvest process with regards to
productivity and product stability, a multi-modal resin (CaptoTM
MMC) was implemented as the capture step (Supplementary
material, Figure S2). The main advantages of this resin were:
(a) its ability to bind FVIII at relatively high salt concentrations,
which minimises protease activity and avoids dilution that would
otherwise prolong the process time; (b) that the column could be
thoroughly washed before product elution, thereby removing
impurities, including proteases, host-cell proteins and DNA (up
to 3 log reduction, Fig. 3a and b) early in the process; and (c) that
the FVIII molecule could be eluted from the column under native
conditions, resulting in a high product recovery (Fig. 3d). After
product load, four steps of washing (Supplementary material,
Table S1) are processed over the multi-modal chromatography
column before product elution. The first wash, Wash 1, mimickedthe conditions in the harvest solution and removed impurities
with no interaction with the capture column. Wash 2, a high-
salt wash step, removed any impurities binding to the resin
through ionic interactions. Wash 3, a low-salt wash, reduced
impurities adhering to the resin through hydrophobic interac-
tions. Wash 4, an ethylene glycol/low arginine wash, was chosen
because it was shown to elute proteins other than FVIII from the
resin through a combinatorial mode. Finally, FVIII was eluted
from the column by increasing the arginine concentration to
0.8 M. Arginine was used based on experimental data showing
good FVIII-eluting properties and its known protein anti-
aggregation properties [40]. FVIII activity was found to be stable
in the eluting buffer for at least 24 h, indicating no, or very low,
protease activity. A subsequent cation-exchange chromatography
step further increases the purity of FVIII, mainly through removal
of host-cell proteins, and ensures a suitable buffer environment
for the subsequent DNA removal step. An SP Sepharose FF
column was found to be robust and reliable for this purpose.
Based on experimental data (Supplementary material, Figures
S3), a single-use anion-exchange membrane was used as a specific
DNA removal step. Depending on DNA reduction of other steps in
the purification process, one or more specific single-use DNA
removal membranes could be introduced in the process. Owing
to the excellent DNA removal properties (9 log) throughout the
entire chosen purification process (Fig. 3b), one specific DNA-
removal step was sufficient. Typically, 1.5–2.5 log reductions in
DNA levels were achieved for the single-use DNA removal mem-
brane with no product loss (Fig. 3d).
The S/D virus inactivation method was included as an extra
safety measure, even though the risk of virus contamination in a
recombinant biopharmaceutical process is in principle negligible.
In-process material was supplemented with 1% Triton X-100 and
0.3% Tri-(n-butyl)-phosphate and incubated at room temperature
for at least 30 min, according to state-of-the-art S/D virus inactiva-
tion practice [41].
An affinity purification step was included, a key step in the
purification process. As the entire production process is free of
animal-derived components, a prerequisite of the intended affinity
ligand was that it should be completely free of animal components.
The affinity ligand chosen was based on a camelid-derived single-
domain antibody fragment expressed in Saccharomyces cerevisiae.
The affinity ligand resin (VIIISelect) was developed in collaboration
between BAC, GE Healthcare and Octapharma. A prototype resin
showed promising purification properties (Fig. 4) and was further
developed to produce a resin with high specificity and stability.
Small-scale cycling studies demonstrated that the VIIISelect col-
umn could be used and regenerated at least 20 times without sig-
nificant decrease in capacity, which was later verified in
production scale (Fig. 5 and Supplementary material, Figure S7).
Furthermore, no leakage of ligand from the resin could be detected
under the selected process conditions (Supplementary material,
Table S3).
The kinetic parameters for binding of VIIISelect ligand to
intact rhFVIII and to its isolated light chain (rhFVIII-LC) were
determined by SPR. No significant difference in association rates
(kass) was observed between the two analytes in any of the bind-
ing buffers tested (Table 1). When tested in HBS-P binding buffer,
the free rhFVIII light chain showed an almost 20-fold higher dis-
sociation rate (kdiss) compared with intact rhFVIII, indicating for-
mation of a less stable complex with the VIIISelect ligand. A
similar 20-fold increase in kdiss was observed for intact rhFVIII
when measured in buffer containing EDTA (HBS-EP). EDTA can
deplete Ca2+ and Cu2+ ions from rhFVIII, which are essential for
conserving the functional structure of rhFVIII. Furthermore, Cu2+
enhances the inter-chain affinity between the heavy and light
chains. Therefore, the observed increase in kdiss is likely due to
S. Winge et al. / Protein Expression and Purification 115 (2015) 165–175 171EDTA-induced formation of free rhFVIII light chains. The presence
of CaCl2 in the buffer (HBS-CP) did not affect the kinetic
parameters for rhFVIII binding.
For rhFVIII-LC, addition of EDTA slightly increased the kdiss
compared with HBS-P, whereas addition of CaCl2 lowered the
dissociation rate. Although Ca2+ ions can alter the conformation
of the FVIII light chain, further studies are required to address this
as a possible cause.
The VIIISelect chromatography column step was shown to
reduce process-related (Fig. 3b), product-related (Figs. 3c and 5b)
and host-cell impurities (Figs. 3a and 5a), resulting in a pure con-
centrated FVIII product fraction with more than 80% recovery
(Fig. 3d).
The product-containing fraction from the VIIISelect column was
diluted and passed through a Planova 20 NTM nanofilter (mean pore
size: 19 nm). Downscaled virus validation studies (nanofilter
membrane surface area: 0.001 m2) confirmed that the nanofiltra-
tion removed one of the smallest known viruses, PPV, by >4 log.
In fact, none of the tested viruses or prions could be detected after
performing the nanofiltration step under selected process condi-
tions (Supplementary material, Table S2).
After nanofiltration, the product was concentrated and further
polished on a Q Sepharose FF anion-exchange chromatography col-
umn that removed trace amounts of host-cell proteins (Supple-
mentary materials, Figure S4 and Figure S5), DNA (Fig. 3b),
process chemicals and FVIII degeneration products (Fig. 3c). The
product recovery was more than 80%.
The final step of human-cl rhFVIII purification is size exclusion
chromatography (SEC) on a Superdex 200 p.g.TM resin (Supplemen-
tary material, Figure S6). The main purpose of this step is furtherFig. 3. (a–d) Purification of FVIII as measured by specific activity (a), DNA content (b), FV
The number of batches used for each calculated value is indicated in the graphs. (a) Pro
specific activity. (b) DNA content after each purification step in production batches, as me
in production batches. (d) FVIII recovery over each purification step in production batchpolishing and preparation (formulation) of the product for the
freeze-drying step. SEC was preferred over ultrafiltration, another
potential technique for formulation, due to its combinatorial prop-
erties of polishing, buffer exchange and removal of aggregates and
fragments. The SEC purification technique fulfilled the high
demand for product stability, purity and quality, in order to opti-
mise patient safety. The product recovery for this step was essen-
tially 100% (Fig. 3d), and the end product fulfilled all set demands
with regards to purity (Figs. 3–6).3.2. Upscaling and validation of the purification process
Upscaled and downscaled process models are critical for estab-
lishment of a robust validated production process. The developed
process was upscaled to a pilot plant scale to be able to produce
material for preclinical and clinical studies, and was thereafter fur-
ther upscaled to a production plant whereby the process validation
takes place to verify purity, quality, safety and recovery under good
manufacturing production conditions. Downscaled process models
are critical to be able to perform virus clearance analyses and resin
cycling studies, which would be costly and inefficient on a larger
scale. The manufacturing process and the equipment used were
in principle comparable in the pilot and production plants. Product
purity, expressed as specific activity (FVIII IU/mg protein), DNA
impurities and process yields were highly comparable across the
three scales: laboratory, pilot and production (Supplementary
material, Figure S7a–c). Thirty-six production batches (twenty-
eight in 100 L and eight in 500 L bioreactor scale) were tested with
no demonstrable changes in product characteristics.III:C/FVIII:Ag ratio (c) and FVIII yield (d) after each step of the purification process.
tein impurities after each purification step in production batches, as measured by
asured by pg DNA/1000 IU FVIII. (c) Ratio FVIII:C/FVIII:Ag after each purification step
es.
1   2    3    4 
Fig. 4. Proof of concept purification of FVIII by chromatography over a prototype
VIIISelect affinity ligand resin, as assessed by silver-stained sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS–PAGE). Lane 1: FVIII control;
lane 2: material before the prototype affinity step; lane 3: flow-through fraction not
binding to the affinity ligand; lane 4: FVIII purified elution fraction.
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active/inactive FVIII) impurities were effectively removed during
the purification process (Fig. 3a–c). As reported previously, the
purified product was free of contamination by viruses and other
pathogens (Supplementary material, Table S2) [17]. The mean FVIII
yield for each purification step was more than 80%, with a yield for
the overall process of 50% (Fig. 3d). SDS–PAGE and Western Blot
analyses (Fig. 5a and b) demonstrated a progressive increase in
purity throughout the production process, with no degradation
products observed in the product eluates after the first capturea
Fig. 5. Silver stained sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS
steps.chromatography purification step. The host cell protein content
in the final product, as analysed with a specific host cell protein
(HCP) assay, was <40 ng/1000 IU FVIII (data not shown), and the
content of DNA in the final product (<10 pg DNA/1000 IU FVIII)
was significantly lower than that required by regulatory demands
(Fig. 3b). Aggregates and fragments, as measured by SEC, corre-
sponded to <2% of the final product (Fig. 6).
3.3. Analyses of leachables from the purification columns
Leached resin was not detected in any of the samples in the
post-column equilibration buffer or in the product eluate fractions
(Supplementary material, Table S3).
4. Discussion
Human-cl rhFVIII (Nuwiq) is a new generation rFVIII product,
without chemical modification or fusion with any other protein
(or protein fragment), produced in a human cell-line. The produc-
tion process for human-cl rhFVIII consists of separate cultivation,
purification and pharmaceutical processes that utilise innovative
techniques, and completely avoids the use of human- or animal-
derived additives [26–32,42,43]. The development of the human
cell-line and purification scheme for human-cl rhFVIII has been
reported previously [17]. The highly pure product was shown to
be fully sulphated, glycosylated similarly to human pdFVIII, and
to have high specific FVIII activity [15,17,18]. Studies in previously
treated children and adults have shown that human-cl rhFVIII is
efficacious in the prevention and treatment of bleeding episodes,
and no patients have developed inhibitors or allergic reactions to
date [19].
The definition of purification is to remove unwanted substances
from a final product. For a biopharmaceutical recombinant process,
such as human-cl rhFVIII production, this includes removal of host-
cell related impurities (e.g., proteins, DNA and potential viruses),b
–PAGE) (a) and Western Blot (b) analyses of samples from each of the purification
Table 1
Kinetic parameters determined by SPR of the VIIISelect ligand in binding to intact
rhFVIII and isolated FVIII light chain under different conditions.
Analyte Binding buffer kass (105 1/Ms) kdiss (104 1/s) KD1 (nM)
rhFVIII HBS-P 3.34 ± 2.34 0.22 ± 0.04 0.07
HBS-EP 4.74 ± 2.92 4.29 ± 1.03 0.91
HBS-CP 1.81 ± 1.00 0.24 ± 0.08 0.13
rhFVIII-
LC
HBS-P 1.71 ± 1.03 4.22 ± 0.55 2.47
HBS-EP 1.38 ± 0.79 8.62 ± 1.36 6.25
HBS-CP 1.04 ± 0.91 1.43 ± 0.32 1.38
kass, rate constant of association; KD, equilibrium dissociation constants; kdiss, rate
constant of dissociation; SPR, surface plasmon resonance.
1 KD calculated as kass/kdiss using average values of both parameters.
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inactivation chemicals and purification step aids) and (potentially)
leachables from equipment (e.g., plastic bags, tubing, filters) and
other material used during the purification process (e.g., chro-
matography resin ligands and support).
During development of a new purification process, there are
several options when selecting the type and number of purification
steps, depending on product properties and demand for purity in
the final product. It is important that the purification process is
designed for maximum removal of known and unknown (e.g.,
pathogenic) impurities. This is especially true for products such
as FVIII that are intended for lifelong treatment. The human-cl
rhFVIII purification process was developed with careful selection
of five chromatography column purification techniques (Fig. 2),
each with a different action to ensure maximum overall reduction
of impurities. The multi-modal cation chromatography column
capture step purifies using a combination of cationic, hydrogen,
thiophilic and hydrophobic interactions. The cation exchange chro-
matography column purification step interacts through negativelyFig. 6. Aggregate and fragment size exclusion chromatography (SEC) analysis chroma
substance). The retention time reflects the molecular size, as detected with a fluorescen
FVIII monomer peak of >99%.charged groups. The affinity chromatography column step inter-
acts with a ligand that has been specifically developed to bind
intact FVIII. The anion exchange chromatography column step
interacts through positively charged groups. The SEC column step
separates according to molecular size. The first four column steps
bind the FVIII molecule. Before FVIII is eluted, the columns are
washed to waste with a total of 130 column volumes of different
wash buffers (Materials and methods 2.4, 2.5, 2.8 and 2.10), con-
tributing to the safety measures for removing all types of potential
impurities.
Chromatography resins can be a source of leachable as impuri-
ties. Leachables for all chromatography column steps in the FVIII
purification process were studied under actual process conditions
and no leaching from any resins was detectable. In addition, all
plastic components (e.g., filters, tubing, bags and ampoules) used
in the production process have been evaluated in terms of leach-
ables. This evaluation included review of materials, supplier infor-
mation, risk analysis and, if deemed necessary, leaching studies
performed under actual processing conditions. All plastic compo-
nents used in the human-cl rhFVIII manufacturing process are cer-
tified according to the requirements of the USP plastic class VI and
are suitable for use in routine production of biopharmaceuticals.
Commercially available rFVIII products are purified based on
chromatographic column purification, which include an affinity
chromatography resin as a key step in the process [22]. An affinity
resin developed based on a single domain antibody (now commer-
cialised as VIIISelect) was used for purification of human-cl rhFVIII.
The kinetic parameters for binding of VIIISelect ligand to intact
rhFVIII and to its isolated light chain (rhFVIII-LC) were determined
by binding affinity studies (SPR). No significant difference in associ-
ation rates (kass) was observed between the two analytes in any of
the binding buffers tested (Table 1), indicating that the epitope
recognised by the VIIISelect ligand is equally accessible on the freetogram of a sample taken after the final human-cl rhFVIII purification step (drug
t detector. The figure shows a typical chromatogram appearance for a human-cl rh
174 S. Winge et al. / Protein Expression and Purification 115 (2015) 165–175FVIII light chain as on intact FVIII molecules. Studies also showed
that the VIIISelect affinity ligand forms a more stable complex with
intact rhFVIII molecules than with free rhFVIII-LC only. As shown
during thedevelopment time [29] and in theproductionprocess val-
idation (Fig. 3c), rhFVIII-LC originating from the cultivation process
was removed during the VIIISelect purification step. A prerequisite
for the development of the affinity resin was that it should be com-
pletely free of animal components, and this was achieved by using
yeast (S. cerevisiae) as the production system for the ligand. The
developed resin was found to have excellent purification properties
(Figs. 3a and 5a), with a product recovery ofmore than 80% (Fig. 3d).
The purification process resulted in a highly pure product, with
a high overall yield of approximately 50%. This yield compares to
the 15% yield reported previously for another rFVIII product [25].
This may be attributable to protection of human-cl rhFVIII from
proteolytic degradation during the cultivation/harvest step, the
propriety [26] non-physiological salt concentration used, and/or
the multi-modal capture chromatography step that includes sev-
eral wash steps to remove potential proteases.
Host cell protein and DNA content were efficiently removed
during the purification process, as analysed by specific activity
(units of FVIII/milligrams of protein, Fig. 3a), silver-stained
SDS–PAGE (Fig. 5a), specific HCP assay (data not shown) and
q-PCR DNA analysis (Fig. 3b). In the final product, host cell protein
content was <40 ng HCP/1000 IU FVIII and DNA content was <10 pg
DNA/1000 IU FVIII, thereby fulfilling all demands for the removal of
these main impurities from the cell cultivation process.
Non-biologically active FVIII molecules were removed during
the later part of the purification process. No detectable FVIII degra-
dation was observed (Fig. 5b) and the ratio of FVIII:C/FVIII:Ag was
close to 1 (Fig. 3c) in the essentially monomeric (170 kD) final pro-
duct (Fig. 6). This finding is potentially of great importance, as inac-
tive product molecules might contribute to inhibitor development
in patients [44].
The use of two dedicated pathogen safeguarding steps for inac-
tivation (S/D) and removal (20 nm nanofiltration) of hypothetically
present pathogens is requested by health authorities for modern
recombinant production processes. The previously reported high
pathogen safety, with regards to viruses and prions, of purified
human-cl rhFVIII [17] was confirmed here (Supplementary mate-
rial, Table S2).5. Conclusion
Validation of the production process demonstrated that all
requirements for a robust and reproducible manufacturing process
were fulfilled, and that the production process is suitable for com-
mercial production. Human-cl rhFVIII could be produced in biore-
actors of up to 500 L and further purified resulting in high purity
and high recoveries.
The quality demands for new biopharmaceutical products have
increased over recent years as technology has developed and safety
requirements have become more stringent. The human-cl rhFVIII
production process has utilised the most innovative technology
and combined a plethora of knowledge and experience to develop
a highly innovative and effective method for commercial-scale pro-
duction of an essentially monomeric human-cl rhFVIII product
with high specific activity [26–28,30–32,42,43].Conflicts of interest
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